Protocol 331-13-009: An Exploratory, Multicenter, Randomized, Double-Blind, fMRI Study of Fixed-dose Brexpiprazole (OPC-34712) (2 and 4 mg/Day Tablets) in Adults With Schizophrenia With Impulsivity
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics; Registrational
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 11 Aug 2016 Status changed from recruiting to completed.
- 29 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.
- 29 Jan 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.